

## **HYPSARRHYTHMIA S1. SECONDARY OUTCOME: RESOLUTION OF CLINICAL SPASMS AND HYPSARRHYTHMIA**

**Evaluation of the literature.** Providing an estimate of the secondary composite outcome (resolution of both clinical spasms and hypsarrhythmia) would require that this composite outcome is clearly quantifiable and similar between different studies. An evaluation of the existing literature on this topic showed that:

- Not all patients with infantile spasms had hypsarrhythmia in the pre-treatment electroencephalogram (EEG) <sup>1-5</sup>, making it difficult to interpret the value of not having hypsarrhythmia in the follow-up EEG among patients who did not have hypsarrhythmia at baseline. Additionally, some patients with no hypsarrhythmia in the pre-treatment EEG had hypsarrhythmia in the follow-up EEG <sup>4</sup>.

- Not all patients who had clinical resolution of spasms had a follow-up EEG <sup>4,6</sup>.

- There is an enormous variability in the time of the follow-up EEG from days to months after treatment initiation <sup>7,8</sup>. Some studies performed follow-up EEG within a narrow time period, for example, days 12 to 19 after treatment initiation <sup>4</sup>, within 2-4 weeks of treatment initiation <sup>9</sup>, or at 1 month of treatment initiation <sup>6</sup>. Other studies considered EEG normalization within a wide range from 12 to 55 days after treatment initiation <sup>10</sup>. Some other studies performed EEGs frequently, twice per week <sup>11</sup>, or after 10 and 20 days of spasms resolution <sup>12</sup>. Further, other studies evaluated resolution of hypsarrhythmia with a later EEG: 3 months after treatment initiation <sup>3</sup>. Importantly, many studies did not provide the time of the follow-up EEG <sup>1,2,13</sup>.


- The definition of resolution of hypsarrhythmia varied widely in the literature. Some studies had a strict definition that considered hypsarrhythmia resolved only if the EEG was completely normal <sup>14</sup> or only has focal epileptiform discharges <sup>15</sup>. Other studies had more lax definitions considering that

resolution of hypsarrhythmia during wakefulness (even if hypsarrhythmia was still present during sleep) was a partial remission<sup>16, 17</sup>. Importantly, many studies did not specify the criteria to determine resolution of hypsarrhythmia<sup>1, 10, 11, 13, 18, 19</sup>. In the context of subjectivity and low inter-rater concordance in the recognition of hypsarrhythmia<sup>20</sup>, it appears that what has been defined as resolution of hypsarrhythmia in one study might not have been defined as such in a different study. We could only find one study with quantifiable and reproducible evaluations of the resolution of hypsarrhythmia<sup>8, 21</sup>.


-Most studies did not specify whether hypsarrhythmia resolution occurred while the patient was still spasms free. Therefore, it could be that a patient had spasms resolution at day 14, but by the time the resolution of hypsarrhythmia was evaluated, the patient was not spasms free anymore. In some studies the number of patients with resolution of hypsarrhythmia is higher than the number of patients with resolution of clinical spasms<sup>10</sup>.

For all the reasons above, we consider that evaluating the composite secondary outcome of resolution of both clinical spasms and hypsarrhythmia is at a very high risk of bias. We provide this composite secondary outcome as it was one of the study objectives, but caution the reader that no firm conclusions can be derived from it. However, trying to summarize the literature identifies the need for more homogeneous definitions of resolution of hypsarrhythmia.


**Meta-analysis on effectiveness.** For this composite secondary outcome, we considered a very lax definition of resolution of clinical spasms at 14-28 days and EEG resolution of hypsarrhythmia (heterogeneously defined) in the corresponding follow-up EEG (performed at varying time periods). Entering these data (from Table e-1 at [https://ivansanchezfernandez.github.io/CE\\_InfantileSpasms/Table\\_S1.pdf](https://ivansanchezfernandez.github.io/CE_InfantileSpasms/Table_S1.pdf)) in the meta-analysis App at [https://bchis.shinyapps.io/metaanalysis\\_probability\\_spasmsresolution/](https://bchis.shinyapps.io/metaanalysis_probability_spasmsresolution/) yields the following results:



FUNNEL PLOT FOR ACTH:




FUNNEL PLOT FOR ORAL STEROIDS:




ACTH appears to be more effective (0.68, 95% CI: 0.56 to 0.78) than oral steroids (0.52, 95% CI: 0.44 to 0.61), but there is marked between-study variability, especially for ACTH, and there is substantial publication bias, especially for ACTH. These results should be considered with caution given that the only study with a quantifiable and reproducible way to evaluate resolution of hypsarrhythmia found that EEG resolution was better with prednisolone than with ACTH <sup>8, 21</sup>.


Further, adjusting for publication bias shows that the apparent superior effect of ACTH was likely due to publication bias:



FUNNEL PLOT FOR ACTH:



FUNNEL PLOT FOR ORAL STEROIDS:



**Cost-effectiveness.** Although we showed that these estimates are likely biased and not reliable, we present the cost-effectiveness analyses for illustration purposes.

Entering the data from the unadjusted estimation of effectiveness (ACTH: 0.68 and prednisolone: 0.52) in the cost-effectiveness App at [https://bchis.shinyapps.io/cost\\_effectiveness/](https://bchis.shinyapps.io/cost_effectiveness/) yielded the following results:


**COST-EFFECTIVENESS TABLE**

Names	Cost	Effectiveness	IE	IC	ICER
No treatment	0.00	0.00	0.00	0.00	NA
Prednisolone	210.00	0.52	0.52	210.00	403.85
ACTH	100464.00	0.68	0.16	100254.00	626587.50

\*Strategies that are not cost-effective dissappear from the table

Legend: IE: incremental effectiveness. IC: incremental cost. ICER: incremental cost-effectiveness ratio.

**COST-EFFECTIVENESS PLOT**



Legend: Notreatment: No treatment. ACTH: Intramuscular ACTH. PRD: Oral prednisolone. \$: USA dollars. SR: Probability of spasms resolution.

The ICER for prednisolone was \$404 per case of spasms resolved. The ICER for ACTH was \$626,588 per case of spasms resolved.

Entering the data from the estimation of effectiveness adjusted for publication bias (ACTH: 0.53 and prednisolone: 0.52) in the cost-effectiveness App at [https://bchis.shinyapps.io/cost\\_effectiveness/](https://bchis.shinyapps.io/cost_effectiveness/) yielded the following results:


**COST-EFFECTIVENESS TABLE**

Names	Cost	Effectiveness	IE	IC	ICER
No treatment	0.00	0.00	0.00	0.00	NA
Prednisolone	210.00	0.52	0.52	210.00	403.85
ACTH	100464.00	0.53	0.01	100254.00	10025400.00

\*Strategies that are not cost-effective dissappear from the table

Legend: IE: incremental effectiveness. IC: incremental cost. ICER: incremental cost-effectiveness ratio.

**COST-EFFECTIVENESS PLOT**



Legend: Notreatment: No treatment. ACTH: Intramuscular ACTH. PRD: Oral prednisolone. \$: USA dollars. SR: Probability of spasms resolution.

The ICER for prednisolone was \$404 per case of spasms resolved. The ICER for ACTH was \$10,025,400 per case of spasms resolved.

**Conclusion.** The main conclusion of this section is that the current literature does not allow a reliable estimate of the composite secondary outcome of resolution of both clinical spasms and hypsarrhythmia, and this estimation is at very high risk of bias. We provided this composite secondary outcome as it was one of the study objectives and for illustration purposes, but caution the reader that no firm conclusions can be derived from it. However, trying to systematically summarize the literature identified the need for more homogeneous definitions of resolution of hypsarrhythmia.

## REFERENCES

1. Chellamuthu P, Sharma S, Jain P, Kaushik JS, Seth A, Aneja S. High dose (4 mg/kg/day) versus usual dose (2 mg/kg/day) oral prednisolone for treatment of infantile spasms: an open-label, randomized controlled trial. *Epilepsy Res* 2014;108:1378-84.
2. Hodgeman RM, Kapur K, Paris A, Marti C, Can A, Kimia A, et al. Effectiveness of once-daily high-dose ACTH for infantile spasms. *Epilepsy & behavior : E&B* 2016;59:4-8.
3. Knupp KG, Coryell J, Nickels KC, Ryan N, Leister E, Loddenkemper T, et al. Response to treatment in a prospective national infantile spasms cohort. *Ann Neurol* 2016;79:475-84.
4. Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. *Lancet* 2004;364:1773-8.
5. Ware TL, Mackay MT, Harvey AS, Freeman JL. Epileptic spasms: experience with a high-dose oral corticosteroid protocol. *Journal of paediatrics and child health* 2012;48:985-9.
6. Kossoff EH, Hedderick EF, Turner Z, Freeman JM. A case-control evaluation of the ketogenic diet versus ACTH for new-onset infantile spasms. *Epilepsia* 2008;49:1504-9.
7. Kossoff EH, Hartman AL, Rubenstein JE, Vining EP. High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH. *Epilepsy & behavior : E&B* 2009;14:674-6.
8. Wanigasinghe J, Arambepola C, Sri Ranganathan S, Sumanasena S, Attanapola G. Randomized, Single-Blind, Parallel Clinical Trial on Efficacy of Oral Prednisolone Versus Intramuscular Corticotropin on Immediate and Continued Spasm Control in West Syndrome. *Pediatric neurology* 2015;53:193-9.
9. Gonzalez-Giraldo E, Stafstrom CE, Stanfield AC, Kossoff EH. Treating Infantile Spasms with High-Dose Oral Corticosteroids: A Retrospective Review of 87 Children. *Pediatric neurology* 2018;87:30-5.
10. Cohen-Sadan S, Kramer U, Ben-Zeev B, Lahat E, Sahar E, Nevo Y, et al. Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. *European journal of neurology* 2009;16:482-7.
11. Yanagaki S, Oguni H, Hayashi K, Imai K, Funatuka M, Tanaka T, et al. A comparative study of high-dose and low-dose ACTH therapy for West syndrome. *Brain Dev* 1999;21:461-7.
12. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. *Epilepsia* 1997;38:1270-4.
13. Lin HC, Young C, Wang PJ, Lee WT, Shen YZ. ACTH therapy for Taiwanese children with West syndrome -- efficacy and impact on long-term prognosis. *Brain Dev* 2006;28:196-201.
14. Snead OC, 3rd, Benton JW, Jr., Hosey LC, Swann JW, Spink D, Martin D, et al. Treatment of infantile spasms with high-dose ACTH: efficacy and plasma levels of ACTH and cortisol. *Neurology* 1989;39:1027-31.
15. Dressler A, Benninger F, Trimmel-Schwahofer P, Groppel G, Porsche B, Abraham K, et al. Efficacy and tolerability of the ketogenic diet versus high-dose adrenocorticotrophic hormone for infantile spasms: A single-center parallel-cohort randomized controlled trial. *Epilepsia* 2019;60:441-51.
16. Yi Z, Wu H, Yu X, Zha J, Chen H, Chen Y, et al. High-dose prednisone therapy for infantile spasms and late-onset epileptic spasms in China: The addition of topiramate provides no benefit. *Seizure* 2019;71:174-8.
17. Yi ZS, Wu HP, Yu XY, Chen Y, Zhong JM. Efficacy and tolerability of high-dose prednisone in Chinese children with infantile spasms. *Brain Dev* 2015;37:23-8.
18. Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. *Pediatrics* 1996;97:375-9.
19. Yin J, Lu Q, Yin F, Wang Y, He F, Wu L, et al. Effectiveness and Safety of Different Once-Daily Doses of Adrenocorticotrophic Hormone for Infantile Spasms. *Paediatric drugs* 2017;19:357-65.



20. Hussain SA, Kwong G, Millichap JJ, Mytinger JR, Ryan N, Matsumoto JH, et al. Hypsarrhythmia assessment exhibits poor interrater reliability: a threat to clinical trial validity. *Epilepsia* 2015;56:77-81.
21. Wanigasinghe J, Arambepola C, Sri Ranganathan S, Sumanasena S, Muhandiram EC. The efficacy of moderate-to-high dose oral prednisolone versus low-to-moderate dose intramuscular corticotropin for improvement of hypsarrhythmia in West syndrome: a randomized, single-blind, parallel clinical trial. *Pediatric neurology* 2014;51:24-30.